

October 28, 2008

AnGes MG, Inc.

Therapeutic Effects of GEN0101 on Hormone-Refractory Prostate Cancer Confirmed  
- Announcement of Results of Animal Studies at the  
67th Japanese Cancer Association General Meeting -

The research group of Professor Yasufumi Kaneda at Osaka University Graduate School of Medicine, who are conducting a collaborative research with AnGes MG Inc. (AnGes MG)'s subsidiary, GenomIdea Inc. (GenomIdea), will announce the results of animal studies showing that GEN0101 (HVJ-E) has therapeutic effects on hormone-refractory prostate cancer at the 67th Japanese Cancer Association general meeting in Nagoya City on October 28.

This research using hormone-refractory prostate cancer cells transplanted mice as cancer animal models demonstrated that after treatment with GEN0101, prostate cancer shrunk, and in some individuals cancer was eradicated. The mechanism of action in which GEN0101 has therapeutic effects on prostate cancer was also analyzed. The results showed that besides activating cancer immunity, GEN0101 directly acts on prostate cancer cells and kills them. There were also results showing that GEN0101 acts more strongly on hormone-refractory prostate cancer than on other types of prostate cancer.

Although treatment by hormone therapy is effective in its early stages, prostate cancer is known to progress to hormone-refractory prostate cancer a few years after commencement of treatment. Therefore, there is a great need for the development of excellent therapeutic drugs for hormone-refractory prostate cancer, which is a very serious type. This announcement by the research group of Professor Kaneda at Osaka University gives support to the product concept of developing GEN0101 as a therapeutic drug for hormone-refractory prostate cancer, and contains findings of great importance in its pursuit of the development. GenomIdea and its alliances are going to pursue preclinical trials, aiming at an early start of clinical trials, so that such an all-Japanese therapeutic drug for cancer with a new concept shall be offered to patients at the earliest possible date.

As noted in the released materials dated October 9, GenomIdea entered into a basic

agreement with TSD Japan, Inc. (TSD) on license contract concerning development of GEN0101 as a drug for prostate cancer. This announcement carries contents which give support to the development of therapeutic drugs for hormone-refractory prostate cancer, which is the object of this alliance. Concerning this announcement, Mr. Yoshiharu Sakashita, CEO of TSD, comments as follows:

“TSD is going to pursue the development of GEN0101 targeting hormone-refractory prostate cancer, so the fact that its definite effects on hormone-refractory prostate cancer were observed in animals will be a very assuring support to us. Generally, most immunotherapeutic drugs show only nonspecific effects. The announcement of the data of animal studies showing the efficacy of GEN0101 on prostate cancer, which is our clinical target, especially on hormone-refractory prostate cancer, suggests a high possibility of finding its efficacy in clinical trials. Also, we are greatly encouraged by the results showing the mechanism of action in which GEN0101 directly kills prostate cancer and its particularly strong effects on hormone-refractory prostate cancer, which allow us to foresee favorable results in clinical trials. On the basis of the evidence of pharmacological effects of GEN0101 including these results, TSD Japan is going to make concerted and united efforts so that this new drug can contribute to the treatment of actual prostate cancer as soon as possible.”

Mr. Toshihiro Nakajima, CEO of GenomIdea, comments as follows:

“So far, the research group of Professor Kaneda at Osaka University has shown the data of animal studies indicating that GEN0101 is effective in the treatment of colorectal cancer and renal cancer. The announcement revealing that it has therapeutic effects on hormone-refractory prostate cancer as well as on these cancers will help our project to make a great advance. While prostate cancer is expected to become one of the major cancers in males with the aging of population, at present there is only one anticancer drug approved for hormone-refractory prostate cancer in Japan. Therefore, there is a need for the development of a new therapeutic drug. Aiming for its development, we hope to advance our project steadily in corporation with TSD.

<Reference>  
- Company Profile -

Company name : TSD Japan, Inc.  
Head office : 1-15-2 Nishinakajima, Yodogawa-ku, Osaka  
Representative : Yoshiharu Sakashita, President and CEO  
Established : July 2005  
Capital : 734 million yen (October 2008)  
Employees : 50 (September 2008)  
Sales : 174 million yen (term ending September 2008)  
Scope of Business : 1. Value-added partnering to assist affiliations between domestic and foreign bio-venture companies and pharmaceutical companies in Japan  
2. Contract clinical studies service (CRO Business)  
Major shareholder (equity ratio) : Daiwa SMBC Capital (35%)

Company name : GenomIdea, Inc.  
Head office : 7-7-15 Saito-Asagi, Ibaraki-shi, Osaka  
Representative : Toshihiro Nakajima, CEO  
Established : July 2002  
Capital : 348 million yen (December 2007)  
Employees : 21 (December 2007)  
Sales : 75 million yen (term ending December 2007)  
Scope of Business : Research and development of new drugs and new vector technologies  
Major shareholder (equity ratio) : AnGes MG, Inc. (72%)